- Report
- March 2024
- 194 Pages
Global
From €3263EUR$3,374USD£2,763GBP
€3625EUR$3,749USD£3,070GBP
- Report
- February 2024
- 175 Pages
Global
From €4835EUR$5,000USD£4,095GBP
- Report
- November 2023
- 178 Pages
Global
From €4739EUR$4,900USD£4,013GBP
- Report
- February 2024
- 232 Pages
Global
From €3481EUR$3,600USD£2,948GBP
- Report
- February 2024
- 119 Pages
Asia Pacific
From €1451EUR$1,500USD£1,228GBP
- Report
- February 2024
- 108 Pages
North America
From €1451EUR$1,500USD£1,228GBP
- Report
- February 2024
- 118 Pages
Middle East, Africa
From €1451EUR$1,500USD£1,228GBP
- Report
- February 2024
- 118 Pages
Europe
From €1451EUR$1,500USD£1,228GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1934EUR$2,000USD£1,638GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1934EUR$2,000USD£1,638GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1209EUR$1,250USD£1,024GBP
- Report
- March 2024
- 191 Pages
Global
From €3263EUR$3,374USD£2,763GBP
€3625EUR$3,749USD£3,070GBP
- Clinical Trials
- April 2024
- 80 Pages
Global
From €1934EUR$2,000USD£1,638GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1934EUR$2,000USD£1,638GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1934EUR$2,000USD£1,638GBP
- Report
- April 2023
- 120 Pages
Global
From €4594EUR$4,750USD£3,890GBP
- Report
- August 2022
- 79 Pages
Global
From €7253EUR$7,500USD£6,142GBP
- Report
- January 2022
- 200 Pages
Global
From €7253EUR$7,500USD£6,142GBP
- Report
- January 2022
- 60 Pages
Global
From €3820EUR$3,950USD£3,235GBP
- Report
- January 2022
- 60 Pages
Global
From €3820EUR$3,950USD£3,235GBP
The Conjunctivitis Drug market is a subset of the Optical Disorders Drugs market, which includes drugs used to treat a variety of eye conditions. Conjunctivitis is an inflammation of the conjunctiva, the thin, transparent membrane that lines the inner surface of the eyelids and covers the white part of the eye. Conjunctivitis drugs are used to treat the symptoms of the condition, such as redness, itching, and discharge. These drugs can be administered topically, orally, or intravenously, depending on the severity of the condition. Commonly prescribed drugs for conjunctivitis include antibiotics, antihistamines, and corticosteroids.
The Conjunctivitis Drug market is highly competitive, with a number of companies offering a variety of products. Some of the major players in the market include Allergan, Bausch + Lomb, Merck, Novartis, Pfizer, and Santen Pharmaceuticals. Show Less Read more